When was BriaCell Therapeutics founded?

BriaCell Therapeutics was founded in 2004 and raised its 1st funding round 10 years after it was founded.

Where is BriaCell Therapeutics located?

BriaCell Therapeutics is headquartered in Beverly Hills, United States.

How many employees does BriaCell Therapeutics have?

As of Jul 31, 2026, the latest employee count at BriaCell Therapeutics is 24.

Is BriaCell Therapeutics a funded company?

BriaCell Therapeutics is a funded company, having raised an undisclosed amount across 20 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on May 23, 2014.

When was the latest funding round of BriaCell Therapeutics?

BriaCell Therapeutics' latest funding was a $***** Grant (prize money) round on Aug 22, 2025, with participation from 1 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $1.97B in funding in 2026 to date.

Where does BriaCell Therapeutics rank among its competitors?

BriaCell Therapeutics ranks 227th amongst 3338 active competitors, of which 1122 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of BriaCell Therapeutics?

BriaCell Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

BriaCell Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of immunotherapies for the treatment of cancer. Its lead product candidate, Bria-IMT is a genetically engineered whole-cell vaccine derived from a human breast cancer cell line. Bria-IMT is used in combination with multiple immune modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells. Another product Bria-OTS is shelf-personalized immunotherapy for the treatment of advanced-stage breast cancer.

Website: briacell.com
Social
Email ID: *****@BriaCell.com

Key Metrics

Founded Year

2004

Location

Beverly Hills, United States

Stage

Public

Latest Funding Round

Grant (prize money), Aug 22, 2025, $*****

Investors

National Cancer Institute & 6 more

Ranked

227^th among 3338 active competitors

Employee Count

24 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3010 more

Exit Details

Public

View BriaCell Therapeutics' full profile

BriaCell Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BRIACELL THERAPEUTICS CORP. CIN: 1610820 , United States, Active	Apr 02, 2014	-	16 (As on Jul 31, 2023)	-
BriaCell Therapeutics Corp CIN: 47-1099599 , United States, Active	Apr 02, 2014	-	-	-

BriaCell Therapeutics got listed on Nov 01, 2010.

Click here to take a look at BriaCell Therapeutics's IPO in detail

BriaCell Therapeutics has raised funding over 20 rounds. Its first funding round was on May 23, 2014. Its latest funding round was a Grant (prize money) round on Aug 22, 2025 for $*****. 1 investor participated in its latest round. BriaCell Therapeutics has 6 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of BriaCell Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 22, 2025	2302295	Grant (prize money)	9232227	8508037	6111012	6948635
Jan 08, 2025	1139401	Grant (prize money)	2000443	3557756	3641502	HHS
Sep 01, 2023	4766654	Grant (prize money)	7867269	1351396	4853379	HHS

Access funding benchmarks and valuations. Sign up today!

View details of BriaCell Therapeutics's funding rounds and investors

The founders of BriaCell Therapeutics is Charles Wiseman. William Williams is the CEO of BriaCell Therapeutics.

Here are the details of BriaCell Therapeutics' key team members:

Charles Wiseman: Co- Founder of BriaCell Therapeutics.

View details of BriaCell Therapeutics's Founder profiles and Board Members

BriaCell Therapeutics' employee count trend

BriaCell Therapeutics has 24 employees as of Jul 26. Here is BriaCell Therapeutics's employee count trend over the years:

Employee count trend for BriaCell Therapeutics

Uncover BriaCell Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BriaCell Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of BriaCell Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
227th	BriaCell Therapeutics 2004, Beverly Hills (United States), Public	Developer of immunotherapies for the treatment of cancer	-	National Cancer Institute, ThinkEquity & 5 others	58/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on BriaCell Therapeutics's competitors? Click here to see the top ones

BriaCell Therapeutics has made no investments or acquisitions yet.

Here is the latest report on BriaCell Therapeutics's sector:

Free

Oncology - Sector Report

Edition: August, 2026 (74 Pages)

View all reports related to BriaCell Therapeutics

Media has covered BriaCell Therapeutics for a total of 31 events in the last 1 year, 19 of them have been about company updates and 3 about partnerships.